Human OPM2 Xenograft Model
Objective: To assess the in vivo antitumor activity of HuLuc63 humanized antibody targeting CS1 in a human OPM2 myeloma xenograft model in mice
Gather these items before starting the experiment. Check off items as you prepare.
Equipment1
Not specified in provided text • Not specified in provided text • Not specified in provided text • Not specified in provided text
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Xenograft implantation
Human OPM2 myeloma cells were implanted in mice to establish the xenograft model
Note: This is the foundational step for the in vivo model
View evidence from paper
“in vivo using the human OPM2 xenograft model in mice”
HuLuc63 treatment administration
HuLuc63 antibody was administered to mice bearing OPM2 xenografts to assess antitumor activity
Note: Treatment efficacy depended on Fc-CD16 interaction and presence of NK cells
View evidence from paper
“HuLuc63 exerted significant in vivo antitumor activity, which depended on efficient Fc-CD16 interaction as well as the presence of NK cells in the mice”
Antitumor activity assessment
Evaluation of HuLuc63-mediated antitumor effects in the xenograft model
Note: Activity assessment was conducted in vivo in the xenograft model
View evidence from paper
“HuLuc63-mediated anti-myeloma activity was tested in vitro in antibody-dependent cellular cytotoxicity (ADCC) assays and in vivo using the human OPM2 xenograft model in mice”